TCR2 Therapeutics Inc.
TCRR · NASDAQ
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.16 | -0.11 |
| FCF Yield | -68.28% | -70.68% | -44.11% | -23.02% |
| EV / EBITDA | -1.54 | -36.10 | -2.44 | -4.23 |
| Quality | ||||
| ROIC | -38.68% | -31.61% | -12.11% | -11.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.99 | 0.41 | 0.84 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -46.61% | 10.65% | -19.11% | 22.26% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | -12.69 | -0.14 | -0.63 |
| Interest Coverage | -5.95 | 0.00 | 0.00 | -106.61 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |